Product Information
OCELLA 3 MG-0.03 MG TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.1538 per EA under NDC 00555913167. Its NADAC has been published 658 times since Nov 28, 2013.
FDA first approved this application on May 11, 2001. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00555913167
Classification
Generic
Dosage Form
KIT
Effective Date
6/17/2026
Approval Type
Authorized Generic (NDA)
FDA Application
NDA021098FDA Approved
5/11/2001
TE Code
AB
On Market Since
6/11/2001
Price Statistics
The NADAC for OCELLA 3 MG-0.03 MG TABLET has been published 658 times since Nov 28, 2013, and over the history we have for it it has declined 91.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1538 per EA |
|---|---|
| All-time high | $1.7954 (Feb 12, 2014) |
| All-time low | $0.1517 (Apr 17, 2024) |
| 52-week high | $0.1731 |
| 52-week low | $0.1538 |
| Median price | $0.3642 |
| Average price | $0.6197 |
| Largest weekly change | +27.6% (Jun 19, 2024) |
| Weeks tracked | 658 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
-2.3%
1Y
-3.2%
3Y
-20.0%
5Y
-50.8%
All
-91.1%
Last surveyed Jul 1, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
drospirenone and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OCELLA 3 MG-0.03 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OCELLA 3 MG-0.03 MG TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $0.1538 per EA (NDC 00555913167), effective Jul 1, 2026.
How has the price of OCELLA 3 MG-0.03 MG TABLET changed over time?
Over the history we have for it, the NADAC for OCELLA 3 MG-0.03 MG TABLET has declined 91.1%. It has been tracked across 658 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for OCELLA 3 MG-0.03 MG TABLET?
Since Nov 28, 2013, the NADAC for OCELLA 3 MG-0.03 MG TABLET has ranged from a low of $0.1517 (Apr 17, 2024) to a high of $1.7954 (Feb 12, 2014), with a median of $0.3642 per EA.
Are there cheaper alternatives to OCELLA 3 MG-0.03 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DROSPIRENONE-EE 3-0.03 MG TAB, is $0.1492 per EA — about 3% below OCELLA 3 MG-0.03 MG TABLET.
Who manufactures OCELLA 3 MG-0.03 MG TABLET?
OCELLA 3 MG-0.03 MG TABLET (NDC 00555913167) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.